Cookies
We use essential cookies to run the site. Analytics cookies are optional and help us improve World Wide. Learn more.
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell New York, USA & Charité – Universitätsmedizin Berlin, Berlin, Germany
Showing your local timezone
Schedule
Tuesday, August 31, 2021
8:30 PM Europe/Zurich
Domain
NeuroscienceHost
NeuroLeman Network
Duration
70 minutes
Time and again we are faced with the question at what point in the treatment of schizophrenia a depot formulation should be used. The data on the so-called LAIs (Long-Acting Injectables) has steadily increased in recent years. Today, we have very good evidence for the early use of depot therapies. However, the willingness and consent of the patient for this form of pharmacotherapy remains central to the successful use of LAIs. In his lecture, Prof. Correll will talk about the current evidence for the use of LAIs summarizing the latest studies.
Christoph U. Correll
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell New York, USA & Charité – Universitätsmedizin Berlin, Berlin, Germany
Contact & Resources
neuro
Digital Minds: Brain Development in the Age of Technology examines how our increasingly connected world shapes mental and cognitive health. From screen time and social media to virtual interactions, t
neuro
neuro
Alpha synuclein and Lrrk2 are key players in Parkinson's disease and related disorders, but their normal role has been confusing and controversial. Data from acute gene-editing based knockdown, follow